


WHAT IS CLAIMED IS:


1. Use of a therapeutically effective amount of a compound or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof in the manufacture of a medicament for treating a cancer in a human subject, wherein the compound has the structure:



further wherein the compound is to be administered to the subject at a total daily dose of about 300 mg.


2. The use of claim 1, wherein the compound is to be administered to the subject in a single daily dose.
3. The use of claim 1, wherein the cancer is selected from the group consisting of colorectal cancer, colon cancer, rectal cancer, pancreatic cancer, pancreatic neuroendocrine tumor (PNET), gastroesophageal junction (GEJ) adenocarcinoma, gastric cancer, GEJ/gastric cancer, head and neck cancer, hepatocellular carcinoma (HCC), renal cell cancer (RCC), ovarian cancer, lung cancer, non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), breast cancer, prostate cancer, castration-resistant prostate cancer (CRPC), appendiceal cancer, melanoma, sarcoma, bladder cancer, gastrointestinal stromal tumors (GIST), and thyroid cancer.
4. The use of claim 1, wherein the cancer is colorectal cancer.
5. The use of claim 1, wherein the cancer is refractory.

6. The use of claim 1, wherein the cancer is recurrent.
7. The use of claim 1, wherein the cancer is metastatic.
8. Use of a therapeutically effective amount of a compound or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof in the manufacture of a medicament for treating cancer in a selected patient population whose biological sample is shown to have a NANOG level that is above a benchmark level, wherein the compound has the structure:




9. The use of claim 8, wherein the cancer is selected from the group consisting of colorectal cancer, colon cancer, rectal cancer, pancreatic cancer, pancreatic neuroendocrine tumor (PNET), gastroesophageal junction (GEJ) adenocarcinoma, gastric cancer, GEJ/gastric cancer, head and neck cancer, hepatocellular carcinoma (HCC), renal cell cancer (RCC), ovarian cancer, lung cancer, non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), breast cancer, prostate cancer, castration-resistant prostate cancer (CRPC), appendiceal cancer, melanoma, sarcoma, bladder cancer, gastrointestinal stromal tumors (GIST), and thyroid cancer.
10. The use of claim 8, wherein the cancer is colorectal adenocarcinoma.
11. The use of claim 8, wherein the cancer is refractory.
12. The use of claim 8, wherein the cancer is recurrent.
13. The use of claim 8, wherein the cancer is metastatic.


14. Use of a therapeutically effective amount of a compound or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof in the manufacture of a medicament for treating cancer in a selected patient population whose biological sample is shown to have a STK33 level that is above a benchmark level, wherein the compound has the structure:



15. The use of claim 14, wherein the cancer is selected from the group consisting of colorectal cancer, colon cancer, rectal cancer, pancreatic cancer, pancreatic neuroendocrine tumor (PNET), gastroesophageal junction (GEJ) adenocarcinoma, gastric cancer, GEJ/gastric cancer, head and neck cancer, hepatocellular carcinoma (HCC), renal cell cancer (RCC), ovarian cancer, lung cancer, non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), breast cancer, prostate cancer, castration-resistant prostate cancer (CRPC), appendiceal cancer, melanoma, sarcoma, bladder cancer, gastrointestinal stromal tumors (GIST), and thyroid cancer.
16. The use of claim 14, wherein the cancer is colorectal adenocarcinoma.
17. The use of claim 14, wherein the cancer is refractory.
18. The use of claim 14, wherein the cancer is recurrent.
19. The use of claim 14, wherein the cancer is metastatic.
20. Use of a therapeutically effective amount of a compound or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof in the manufacture of a medicament for treating cancer in a selected patient population whose cell nucleus sample is shown to have significant expression of NANOG, STK33 or both NANOG and STK33, wherein the compound has the structure:



21. The use of claim 20, wherein the cancer is selected from the group consisting of colorectal cancer, colon cancer, rectal cancer, pancreatic cancer, pancreatic neuroendocrine tumor (PNET), gastroesophageal junction (GEJ) adenocarcinoma, gastric cancer, GEJ/gastric cancer, head and neck cancer, hepatocellular carcinoma (HCC), renal cell cancer (RCC), ovarian cancer, lung cancer, non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), breast cancer, prostate cancer, castration-resistant prostate cancer (CRPC), appendiceal cancer, melanoma, sarcoma, bladder cancer, gastrointestinal stromal tumors (GIST), and thyroid cancer.
22. The use of claim 20, wherein the cancer is colorectal adenocarcinoma.
23. The use of claim 20, wherein the cancer is refractory.
24. The use of claim 20, wherein the cancer is recurrent.
25. The use of claim 20, wherein the cancer is metastatic.
26. Use of a therapeutically effective amount of a compound or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof in the manufacture of a medicament for treating cancer in a selected patient population whose biological sample is shown to have a level and/or subcellular localization of one or more cancer stemness markers selected from NANOG and STK33 that is above a benchmark level, wherein the compound has the structure:



27. The use of claim 26, wherein the cancer is selected from the group consisting of colorectal cancer, colon cancer, rectal cancer, pancreatic cancer, pancreatic neuroendocrine tumor (PNET), gastroesophageal junction (GEJ) adenocarcinoma, gastric cancer, GEJ/gastric cancer, head and neck cancer, hepatocellular carcinoma (HCC), renal cell cancer (RCC), ovarian cancer, lung cancer, non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), breast cancer, prostate cancer, castration-resistant prostate cancer (CRPC), appendiceal cancer, melanoma, sarcoma, bladder cancer, gastrointestinal stromal tumors (GIST), and thyroid cancer.
28. The use of claim 26, wherein the cancer is colorectal adenocarcinoma.
29. The use of claim 26, wherein the cancer is refractory.
30. The use of claim 26, wherein the cancer is recurrent.
31. The use of claim 26, wherein the cancer is metastatic.